Novo Nordisk is facing “unprecedented” price pressures, “intensifying competition” and patents expiring.

Read original article

Tags:
Leave a Comment

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *